Angiocol
Latest Information Update: 03 Feb 2017
At a glance
- Originator BioStratum
- Class Antineoplastics; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Feb 2017 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 14 Apr 2004 Angiocol is available for licensing (http://www.biostratum.com)
- 14 Apr 2004 Suspended - Preclinical for Cancer in USA (unspecified route)